|
Supernus Pharmaceuticals inc (NASDAQ: SUPN) |
|
Supernus Pharmaceuticals inc
SUPN's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Supernus Pharmaceuticals Inc growth rates, revenue grew
by 13.18 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1217
Major Pharmaceutical Preparations industry recorded
growth of revenues by 11.85 %
Supernus Pharmaceuticals Inc realized net income compared to net loss a year ago in IV. Quarter 2024
• More on SUPN's Growth
|
|
Supernus Pharmaceuticals Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Supernus Pharmaceuticals Inc PEG ratio is at 0.09
Supernus Pharmaceuticals Inc realized cash reduction of $ -0.1 per share in trailing twelve-month period. |
Company |
23.93 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.66.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.
• More on SUPN's Valuation
|
|
|
|
|
Supernus Pharmaceuticals Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Supernus Pharmaceuticals Inc PEG ratio is at 0.09
Supernus Pharmaceuticals Inc realized cash outflow of $ -0.1per share in trailing twelve-month period. |
Company |
23.93 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.66.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.
Supernus Pharmaceuticals Inc Price to Book Ratio is at 1.7 lower than Industry Avg. of 77.28. and higher than S&P 500 Avg. of 0.01
• More on SUPN's Valuation
|
|
SUPN's Profitability Comparisons
|
Supernus Pharmaceuticals Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in IV. Quarter 2024 to 12.29 % from 23.25 % in III. Quarter.
Supernus Pharmaceuticals Inc net profit margin of 8.8 % is currently ranking no. 48 in Major Pharmaceutical Preparations industry, ranking no. 130 in Healthcare sector and number 1480 in S&P 500.
Profitability by Segment |
Total |
21.91 % |
|
|
Supernus Pharmaceuticals Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in IV. Quarter 2024 to 12.29 % from 23.25 % in III. Quarter.
Supernus Pharmaceuticals Inc net profit margin of 8.8 % is currently ranking no. 48 in Major Pharmaceutical Preparations industry, ranking no. 130 in Healthcare sector and number 1480 in S&P 500.
• More on SUPN's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com